# RYBREVANT FASPRO
> **BLA761433** · Biologics License Application · Sponsor: JANSSEN BIOTECH · Approved 2025-12-17
## Drug
- **FDA Application Number:** BLA761433
- **Application type:** Biologics License Application
- **Brand name:** RYBREVANT FASPRO
- **Generic name:** AMIVANTAMAB AND HYALURONIDASE-LPUJ (HUMAN RECOMBINANT)
- **Active ingredients:** AMIVANTAMAB AND HYALURONIDASE-LPUJ
- **Dosage form:** INJECTION
- **Route:** —
- **Marketing status:** Prescription
- **Sponsor:** JANSSEN BIOTECH
- **Manufacturer:** Janssen Biotech, Inc.
- **First approval:** 2025-12-17
## Source
- [Drugs@FDA application overview](https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761433)
---
*MORVS · CC0 1.0*